13908-39-9

Basic information

• Product Name: 1-(2-chloroethyl)-3-[4-(trifluoromethyl)phenyl]urea
• CAS NO: 13908-39-9
• Molecular Formula: C₁₀H₁₀ClF₃N₂O
• Molecular Weight: 266.6474
• Mol File: 13908-39-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 303.4°C at 760 mmHg
• Flash Point: 137.3°C
• Density: 1.383g/cm³
• Vapor Pressure: 0.000933mmHg at 25°C
• Refractive Index: 1.519
• CAS DataBase Reference: 1-(2-chloroethyl)-3-[4-(trifluoromethyl)phenyl]urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-chloroethyl)-3-[4-(trifluoromethyl)phenyl]urea(13908-39-9)
• EPA Substance Registry System: 1-(2-chloroethyl)-3-[4-(trifluoromethyl)phenyl]urea(13908-39-9)

Safety Data

• Hazardous Substances Data: 13908-39-9(Hazardous Substances Data)

Usage

General Description

1-(2-chloroethyl)-3-[4-(trifluoromethyl)phenyl]urea is a chemical compound with the molecular formula C9H10ClF3N2O. It is a urea derivative that contains a chloroethyl group and a trifluoromethylphenyl group attached to the nitrogen atom. 1-(2-chloroethyl)-3-[4-(trifluoromethyl)phenyl]urea has potential applications in various fields, including pharmaceuticals and agrochemicals. Its precise uses and properties depend on its specific characteristics, and further study and analysis are necessary to fully understand its potential applications and effects.

Upstream product

• 1943-83-5 2-chloroethyl isothiocyanate 
• 455-14-1 4-trifluoromethylphenylamine 

Downstream Products

• 13991-76-9 C₁₀H₉ClF₃N₃O₂ 
• 651748-94-6 2-fluoro-5-[2-oxo-3-(4-trifluoromethyl-phenyl)-imidazolidin-1-yl]-benzoic acid 
• 162748-21-2 1-(4-trifluoromethylphenyl)-2-imidazolidinone 

Relevant articles and documents

Design, synthesis, and screening of sulfonylurea-derived NLRP3 inflammasome inhibitors

Inflammasomes are multiprotein assemblies that produce robust inflammatory responses upon stimulation with pathogen- and/or danger-associated molecular patterns. Uncontrolled inflammasome activation has been linked to the pathophysiology of a wide array of disorders including life-threatening pathogenic infections, e.g., Francisella tularensis. There has been a great deal of interest in the development of small molecule inflammasome inhibitors. Using computational modeling based on chalcone derivatives, we have developed novel tertiary sulfonylurea compounds as inhibitors of the NLRP3 inflammasome. The polar enone functional alert of chalcone was replaced with a sulfonylurea scaffold while maintaining the relative positions of the two aromatic rings. These compounds were evaluated for their ability to inhibit NLRP3 and AIM2 inflammasome activation triggered by Francisella tularensis infection.

Design, synthesis, and biological evaluation of inhibitors of the NADPH oxidase, Nox4

NADPH oxidases (Nox enzymes) are critical mediators of both physiologic and pathophysiologic processes. Nox enzymes catalyze NADPH-dependent generation of reactive oxygen species (ROS), including superoxide and hydrogen peroxide. Until recently, Nox4 was proposed to be involved exclusively in normal physiologic functions. Compelling evidence, however, suggests that Nox4 plays a critical role in fibrosis, as well as a host of pathologies and diseases. These considerations led to a search for novel, small molecule inhibitors of this important enzyme. Ultimately, a series of novel tertiary sulfonylureas (23–25) was designed using pharmacophore modeling, synthesized, and evaluated for inhibition of Nox4-dependent signaling.

UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE

The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.